参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Anal Carcinoma Version 1.2019-March 15, 2019.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.Nelson RA, Levine AM, Bernstein L, et al.Changing patterns of anal canal carcinoma in the United States.J Clin Oncol 2013, 31: 1569-1575.
4.Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, et al.Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal.J Clin Oncol 2014, 32: 1812-1817.
5.Caldarella C, Annunziata S, Treglia G, et al.Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis.Scientific World Journal 2014, 196068.
6.Crehange G, Bosset M, Lorchel F, et al.Combining cisplatin and mitomycin with radiotherapy in anal carcinoma.Dis Colon Rectum 2007, 50: 43-49.
7.Glynne-Jones R, Meadows H, Wan S, et al.EXTRA-a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.Int J Radiat Oncol Biol Phys 2008, 72: 119-126.
8.Goodman K, Rothenstein D, Lajhem C, et al.Capecitabine plus mitomycin in patients undergoing definitive chemoradiation for anal squamous cell carcinoma.Int J Radiat Oncol Biol Phys 2014, 90: S32– S33.
9.Hofheinz RD, Wenz F, Post S, et al.Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.Lancet Oncol 2012, 13: 579-588.
10.O’Connell MJ, Colangelo LH, Beart RW, et al.Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.J Clin Oncol 2014, 32: 1927-1934.(https://www.daowen.com)
11.Meulendijks D, Dewit L, Tomasoa NB, et al.Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.Br J Cancer 2014, 111: 1726-1733.
12.Sekhar H, Zwahlen M, Trelle S, et al.Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study.Lancet Oncol 2017, 18: 1348-1359.
13.Oliveira SC, Moniz CM, Riechelmann R, et al.Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal.J Gastrointest Cancer 2016, 47: 75-81.
14.O’Connell MJ, Colangelo LH, Beart RW, et al.Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.J Clin Oncol 2014, 32: 1927-1934.
15.Morris VK, Salem ME, Nimeiri H, et al.Nivolumab for previously treated unresectable metastatic anal cancer(NCI9673): a multicentre, single-arm, phase 2 study.Lancet Oncol 2017, 18: 446-453.
16.Ott PA, Piha-Paul SA, Munster P, et al.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.Ann Oncol 2017, 28: 1036-1041.
17.Kim DK, Riley LE, Harriman KH, et al.Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older -United States, 2017.MMWR Morb Mortal Wkly Rep 2017, 66: 136-138.
18.Bailey HH, Chuang LT, duPont NC, et al.American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention.J Clin Oncol 2016, 34: 1803-1812.
19.Oliveira SC, Moniz CM, Riechelmann R, et al.Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal.J Gastrointest Cancer 2016, 47: 75-81.
20.Levy A, Azria D, Pignon JP, et al.Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.Radiother Oncol 2015, 114: 415-416.